302 patents
Page 12 of 16
Utility
Methods of Treating Heart Failure with Reduced Ejection Fraction
4 Mar 21
The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Anna Maria LANGKILDE
Filed: 9 Mar 20
Utility
Therapeutic Dendrimers
4 Mar 21
Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
Filed: 11 Nov 20
Utility
Inhibitors of Phosphatidylinositol 3-KINASE Gamma
18 Feb 21
Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
Filed: 4 Nov 20
Utility
Nmda Antagonist Prodrugs
11 Feb 21
Prodrugs of an NMDA antagonist, (S)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.
Gunnar Nordvall, Katharina Högdin, Per Jonas Malmborg, Annika Kers, Dirk Reinhold Weigelt, Peter Robert Bernstein, Michael Quirk, Michael Balestra
Filed: 26 Oct 20
Utility
Chemical Compounds
11 Feb 21
Jeffrey Wallace JOHANNES, Sudhir Mahadeo HANDE, Sebastien Louis DEGORCE, Martin John PACKER
Filed: 17 Jul 20
Utility
Combinations for Treating Cancer
4 Feb 21
Disclosed are methods of treating cancer comprising administering 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6, 12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1 (37), 4(38), 6, 11, 14, 16, 18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, a pharmaceutically acceptable salt thereof; and acalabrutinib, or a pharmaceutically acceptable salt thereof.
Scott BOIKO, Justin CIDADO, Lisa DREW, Theresa PROIA, Maryann SAN MARTIN
Filed: 29 Apr 19
Utility
Tear lipocalin muteins binding IL-4 r alpha
26 Jan 21
The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha.
Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
Filed: 24 Jan 19
Utility
Computer System and Method for Generating Trigger Alerts to Maximize Interactions With Healthcare Providers
21 Jan 21
A pharmaceutical company may employ a computer system that is configured to analyze anonymized patient data for patients treated by each of a plurality of healthcare providers (HCPs) to determine whether each such HCP is likely to make a given type of treatment decision for at least one patient in the foreseeable future.
Kishore Kumar
Filed: 7 Oct 20
Utility
Halo-substituted piperidines as orexin receptor modulators
19 Jan 21
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
Filed: 10 Feb 17
Utility
Inhaler
14 Jan 21
An inhaler for delivery of a medicament by inhalation is disclosed.
BILL TRENEMAN, CHARLOTTE LEEDER, ANDREW HALKET, SIMON INGRAM, CHRIS HURLSTONE, VALERIO LELIO CEREDA, JOE DAINTREY, WARREN ISAACS, MARTIN KARLSSON, JAKE CHRISTOFFERSON, RUNE DUCCE, SIMON BERRY
Filed: 6 Mar 19
Utility
Therapeutic dendrimers
12 Jan 21
Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
Filed: 5 Apr 19
Utility
MCL-1 inhibitors and methods of use thereof
12 Jan 21
Alexander Hird, Wenzhan Yang, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
Filed: 18 Dec 18
Utility
Arginase Inhibitors and Methods of Use Thereof
6 Jan 21
Scott Nathan MLYNARSKI, Tyler GREBE, Sameer KAWATKAR, Maurice Raymond Verschoyle FINLAY, Iain SIMPSON, Jianyan WANG, Steve COOK, Dedong WU
Filed: 14 Feb 19
Utility
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
4 Jan 21
Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
Filed: 26 Sep 19
Utility
Use of Myeloperoxidase (Mpo) Inhibitors or Pharmaceutically Acceptable Salts Thereof to Treat Multiple System Atrophy (Msa) 938
30 Dec 20
The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy.
Hakan Eriksson, Werner Poewe
Filed: 12 Sep 20
Utility
Medicament Dispensing System and Dispensing Method
9 Dec 20
A dispensing system (2) and method for dispensing unit dosage forms (38) from a blister pack (30) is disclosed.
FREDRIK JONSSON, LUBOMIR GRADINARSKY
Filed: 4 Jul 18
Utility
Inhibitors of phosphatidylinositol 3-kinase gamma
7 Dec 20
Mickael Mogemark, Nils Pemberton, Jens Petersen, Matthew Perry, Konstantinos Karabelas, Pavol Zlatoidsky, Rhona Cox, Christian Tyrchan
Filed: 8 Mar 17
Utility
Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
7 Dec 20
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot # P05112 and/or the ligand of Uniprot # P35225 from binding to their respective receptors to a subject in need thereof.
Andreas Hohlbaum, Laurent Audoly, Beverly Koller
Filed: 15 Jul 19
Utility
2-(2,4,5-substituted-anilino)pyrimidine compounds
7 Dec 20
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant).
Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna Kadambar, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui
Filed: 18 Jun 19
Utility
Osimertinib for Use In the Treatment of Non-small Cell Lung Cancer
25 Nov 20
The specification relates to osimertinib or a pharmaceutically acceptable salt thereof for use in the treatment of patients with locally advanced unresectable epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (Stage III), and in particular to the treatment of patients whose disease has not progressed following definitive platinum-based chemoradiation therapy.
Anthony Francis Patrick NASH
Filed: 10 Feb 19